Fate Therapeutics (FATE) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress
November 5, 2019 4:06 PM ESTFirst Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with Rituximab
Received FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen Targeted CAR NK Cell Product Candidate
Opened State-of-the-art cGMP Facility Dedicated to Manufacturing iPSC-derived Cell Therapies
$303 Million in Cash & Short-term Investments as of September 30, 2019 following Completion of $173 Million Common Stock Offering
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company... More
